Centre Léon Berard
Centre Léon Berard
Lyon, France11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) | Brain Damage, Chronic, Neoplasms by Site, Skin and Connective Tissue Diseases, brain disorder, breast disorder, breast neoplasm, central nervous system disorder, cerebral palsy, neoplasm, nervous system disorder, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-08-05 | NCT05215106 | |
| Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-05-14 | NCT05296746 | |
| Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, digestive system neuroendocrine neoplasm, neoplasm, neuroendocrine neoplasm, paraganglioma, pheochromocytoma, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-02-12 | NCT04711135 | |
| Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast cancer, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-01-23 | NCT03878342 | |
| Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Sex Cord-Gonadal Stromal Tumors, gonadal tissue neoplasm, neoplasm | Active, not recruiting | Not applicable | 2025-09-22 | NCT03418844 | |
| High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | High-Risk Neuroblastoma; Patient With Insufficient Response Chemoimmunotherapy | Recruiting | Phase 3 | 2025-06-26 | NCT04221035 | |
| Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 2 | 2025-04-23 | NCT06931704 | |
| Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Recruiting | Phase 2 | 2025-02-19 | NCT03548428 | |
| AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 / Phase 2 | 2025-02-13 | NCT04881032 | |
| Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) | Genital Diseases, Male Urogenital Diseases, Urogenital Diseases, male reproductive system disorder, metastatic prostate carcinoma, prostate disorder | Recruiting | Phase 3 | 2024-12-20 | NCT06496581 | |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, leiomyosarcoma, liposarcoma, myomatous neoplasm, myxoid liposarcoma, neoplasm, sarcoma | Recruiting | Phase 1 / Phase 2 | 2023-05-31 | NCT02275286 |